GOSS
Gossamer Bio, Inc.
$0.33
-4.86%
2026-05-08
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Key Fundamentals
Forward P/E
-1.99
EPS (TTM)
$-0.75
Revenue Growth (YoY)
47.1%
Profit Margin
0.0%
Beta
2.15
Market Cap
$78.0M
Avg Volume (10D)
4.5M
Recent Breakout Signals
No recent breakout signals detected for GOSS.
Recent Price Range (60 Days)
60D High
$2.49
60D Low
$0.32
Avg Volume
15.8M
Latest Close
$0.33
Get breakout alerts for GOSS
Sign up for Breakout Scanner to receive daily notifications when GOSS triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Gossamer Bio, Inc. (GOSS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors GOSS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. GOSS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.